The most common adverse reactions for Wegovy (incidence 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss
Before prescribing semaglutide, a clinician may review: height, weight and BMI waist measurement where relevant weight-related health conditions previous weight-management treatments prescription and non-prescription medicines diabetes history and blood-glucose treatment gastrointestinal symptoms pancreatitis and gallbladder history pregnancy and contraception eating-disorder history relevant medical records or blood-test results treatment expectations long-term weight-management goals The consultation is not simply intended to determine whether a patient meets a BMI threshold
One study, one protocol, one practical tip every Friday: To view or add a comment, sign in #Amylin: A Novel Diabetes & Obesity Therapy Heres my commentary piece from American Diabetes Association #ADA2026 Key take-aways #Amylin is a pancreatic peptide hormone co-secreted with insulin from pancreatic beta-cells
But just like any tool, it only works as hard as you do
You will then receive your monthly supply
This means it stays in your body and exerts its action (to suppress appetite) for a longer time, which helps with weight loss
